Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
Computational challenges in precision medicine and genomicsGary Bader
Genomics is mapping complex data about human biology and promises major medical advances. In particular, genomics is enabling precision medicine, the use of a patient's genome and physiological state to improve therapeutic efficacy and outcome. However, routine use of genomics data in medical research is in its infancy, due mainly to the challenges of working with "Big data". These data are so complex and large that typical researchers are not able to cope with them. Collectively, these data require an understanding of many aspects of experimental biology and medicine to correctly process and interpret. Data size is also an issue, as individual researchers may need to handle tens of terabytes (genomes from a few hundred patients), which is challenging to download and store on typical workstations. To effectively support precision medicine, scientists from a wide range of disciplines, including computer science, must develop algorithms to improve precision medicine (e.g. diagnostics and prognostics), genome interpretation, raw data processing and secure high performance computing.
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
P4 Medicine: A Vision For Your Molecular HealthSachin Rawat
Medicine is undergoing tremendous change. Unlike today, medicine of tomorrow would be pro-active rather than reactive.Medicine would be personalized to individual patient's genome. It would predict, and hence prevent, diseases even before they manifest. Also, this medicine would require active societal participation to bring it from labs to clinics.
Accelerating the benefits of genomics worldwideJoaquin Dopazo
Grand Challenges in Genomics
A Joint NHGRI and Wellcome Trust Strategic Meeting
25 and 26 February 2019
https://www.wellcomeevents.org/WELLCOME/media/uploaded/EVWELLCOME/event_661/Draft_agenda_for_WT_December_2018.pdf
Join lecture: Nicky Mulder, Han Brunner and Joaquin Dopazo
The Foundation of P4 Medicine Keynote Presentation as presented by Leroy Hood, M.D., PhD, at the Ohio State University Personalized Health Care National Conference 2010.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Bioinformatics in the Clinical Pipeline: Contribution in Genomic Medicineiosrjce
In this review report we like to focus on the new challenges in methodology of modern biology be
used in medical science. Today human health is a primary issue to cure disease, undoubtedly the answer to this
is bioinformatics or (In-silco) tools has change the concept of treating patients to understand the need of
genomic medicine in use. Those with new modes of action in clinical treatment, is a major health concern in
medical science. On global prospective scientific role in constructing new ideas to remediate health care to
treat disease exciting in nature is challenging task. So awareness needs to accelerate store clinical datasets for
scientific represents to design genomic drugs. This new outline will drive the medical to discover public data
and create a cognitive approach to use technology cheaper at cost effective mode.
I presented initial insights from 4.5 months engaging with Inuit artists on Baffin Island.
The work would not have been possible without the support of these communities, my translators/interpreters Omalluk Ostiutsiaq, William Kilabuk and Jojo Aningmiuq for the project and of course all project participants. Thank you.
I also acknowledge the support of SSHRC, ArcticNet, West Baffin Eskimo Co-op, Hamlet of Pangnirtung and NSTP making this research possible.
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
P4 Medicine: A Vision For Your Molecular HealthSachin Rawat
Medicine is undergoing tremendous change. Unlike today, medicine of tomorrow would be pro-active rather than reactive.Medicine would be personalized to individual patient's genome. It would predict, and hence prevent, diseases even before they manifest. Also, this medicine would require active societal participation to bring it from labs to clinics.
Accelerating the benefits of genomics worldwideJoaquin Dopazo
Grand Challenges in Genomics
A Joint NHGRI and Wellcome Trust Strategic Meeting
25 and 26 February 2019
https://www.wellcomeevents.org/WELLCOME/media/uploaded/EVWELLCOME/event_661/Draft_agenda_for_WT_December_2018.pdf
Join lecture: Nicky Mulder, Han Brunner and Joaquin Dopazo
The Foundation of P4 Medicine Keynote Presentation as presented by Leroy Hood, M.D., PhD, at the Ohio State University Personalized Health Care National Conference 2010.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Bioinformatics in the Clinical Pipeline: Contribution in Genomic Medicineiosrjce
In this review report we like to focus on the new challenges in methodology of modern biology be
used in medical science. Today human health is a primary issue to cure disease, undoubtedly the answer to this
is bioinformatics or (In-silco) tools has change the concept of treating patients to understand the need of
genomic medicine in use. Those with new modes of action in clinical treatment, is a major health concern in
medical science. On global prospective scientific role in constructing new ideas to remediate health care to
treat disease exciting in nature is challenging task. So awareness needs to accelerate store clinical datasets for
scientific represents to design genomic drugs. This new outline will drive the medical to discover public data
and create a cognitive approach to use technology cheaper at cost effective mode.
I presented initial insights from 4.5 months engaging with Inuit artists on Baffin Island.
The work would not have been possible without the support of these communities, my translators/interpreters Omalluk Ostiutsiaq, William Kilabuk and Jojo Aningmiuq for the project and of course all project participants. Thank you.
I also acknowledge the support of SSHRC, ArcticNet, West Baffin Eskimo Co-op, Hamlet of Pangnirtung and NSTP making this research possible.
When the Human Genome Project was declared complete back in 2003, there were high expectations set for genomic medicine. However, it has taken over a decade to begin moving from vision to reality. Today, the number of success stories remains relatively small, but they do stretch across the healthcare ecosystem, incorporating the prediction of drug responses, the diagnosis of diseases and the identification of targeted therapies. Stakeholders ranging from patients, healthcare providers and payers, researchers, diagnostic companies, policy-makers, life sciences businesses and governments now believe genomic medicine to be a potential game-changer
The role of genomics in drug discovery and development.pdfTaimoor Khan
The role of genomics in this fast-paced world of pharmaceutical research is a powerful catalyst, revolutionizing the entire process. By harnessing the potential of genomics, scientists can uncover valuable insights into disease mechanisms, identify therapeutic targets, and accelerate the discovery and development of groundbreaking medicines. This article dives deep into the significance of genomics in drug discovery and development, highlighting well-known genomic-based drug development services that are driving the future of pharmaceutical therapies.
TCGC The Clinical Genome Conference 2015Nicole Proulx
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.
Death prompts a review of gene therapy vectorLindsay Meyer
Case study and analysis of Targeted Genetics' adeno-associated virus, tgAAC94. Includes overview of clinical trial design, FDA action, NIH investigation, and outcomes surrounding the death of a patient enrolled in the investigational trial.
An Introduction to Bioinformatics
Drexel University INFO648-900-200915
A Presentation of Health Informatics Group 5
Cecilia Vernes
Joel Abueg
Kadodjomon Yeo
Sharon McDowell Hall
Terrence Hughes
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Similar to The role of genomic medicine in transforming healthcare (20)
Welcome to the age of cognitive computing: where intelligent machines have
moved from the realms of science fiction to the present day. This groundbreaking
technology is driving advanced discoveries and allowing improved decision-making –
resulting in better patient care
Eco friendly: The emerging life sciences ecosystem Heather Fraser
Pharma and life sciences collaborations will be taken to a whole new level as emerging ecosystems shake up traditional practices. The emphasis on operations for mutual self-interest and broader benefit will spur openness to innovate and the free flow of ideas and resources.
After the Human Genome Project was completed in 2003, early successes in genomic medicine fell short of the initial
high expectations. But today, a potent mix of influences — including innovation in biology and technology, market demand and consumerism — is furthering an evolution that crosses industries. Healthcare providers can now personalize care plans thanks to lower sequencing
costs that allow genomic data to be combined with electronic health data. Life sciences companies can develop targeted therapies that prevent and alleviate disease symptoms. To capitalize on new advances
in science, cognitive computing, analytics and drug discovery, senior leaders across the ecosystem should act quickly to: make genomic medicine a key component of enterprise strategy; address relevant skill gaps; and determine how partnering can bolster critical capabilities.
The convergence of separate health systems has led to
a great increase in data, which some organisations are
struggling to get to grips with. Harnessing analytic tools
and sharing knowledge is the best way forward
Health device makers, to date, have primarily targeted consumers who are either fitness focused or chronically ill. But between these two extremes sits a large, fragmented and often overlooked population who seek better information to effectively manage their health. Our research suggests that successful solution providers will approach this market opportunity as an ecosystem of partners – with an integrated solution that extends beyond the device itself. By plugging the information gap for these consumers, solution providers can help fuel healthcare innovation.
IBM_analytics across the healthcare ecosystem Heather Fraser
Analytics is a key enabler for life sciences and healthcare organizations to create better outcomes for patients, customers and other stakeholders across the entire healthcare ecosystem. While almost two-thirds of organizations across the healthcare ecosystem have analytics strategies in place, our research shows that only a fifth are driving analytics adoption across the enterprise. The key barriers are a lack of data management capabilities and skilled analysts, as well as poor organizational change management. To develop and translate insights into actions that enhance outcomes, organizations will need to collaborate across an expanding ecosystem.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.